BiomX (PHGE) has issued an update.
BiomX Inc. successfully completed its acquisition of Adaptive Phage Therapeutics on March 15, 2024, resulting in board changes and the issuance of warrants for common stock. This move signifies a strategic expansion for BiomX, with new directors appointed and previous ones resigning without disputes. In tandem, BiomX executed a private placement of Series X preferred stock and additional warrants, further solidifying its financial and strategic position in the market.
Learn more about PHGE stock on TipRanks’ Stock Analysis page.
